西黄胶囊联合他莫昔芬治疗乳腺增生症患者的临床效果及对性激素指标的影响  

Clinical Effect of Xihuang Capsules Combined with Tamoxifen in the Treatment of Breast Hyperplasia and Its Influence on Sex Hormone Indexes

作　　者：王志超[1] 徐枫[1] WANG Zhichao;XU Feng(Jiamusi Maternal and Child Health Hospital,Heilongjiang Province,Jiamusi 154002,China;不详)

机构地区：[1]黑龙江省佳木斯市妇幼保健院,黑龙江佳木斯154002

出　　处：《中国医学创新》2022年第16期61-65,共5页Medical Innovation of China

摘　　要：目的:探讨西黄胶囊联合他莫昔芬治疗乳腺增生症患者的临床效果及对性激素指标的影响。方法:选取2019年1月-2020年12月佳木斯市妇幼保健院收治的106例乳腺增生症患者,按照随机数字表法将其分为对照组和研究组,每组53例。对照组口服他莫昔芬治疗,研究组口服西黄胶囊联合他莫昔芬治疗。比较两组血清血管内皮生长因子(VEGF)、碱性成纤维细胞生长因子(bFGF)水平、性激素[睾酮(T)、催乳激素(PRL)、黄体生成激素(LH)、促卵泡成熟激素(FSH)、雌二醇(E_(2))]、乳腺症状评分、不良反应发生情况及生活质量情况。结果:治疗后,两组血清VEGF、bFGF水平均低于治疗前,且研究组均低于对照组,差异均有统计学意义(P<0.05)。治疗后,两组PRL、FSH、LH、T、E_(2)水平均低于治疗前,且研究组均低于对照组,差异均有统计学意义(P<0.05)。治疗后,两组乳房肿块硬度、乳腺肿块大小、乳腺疼痛评分均低于治疗前,且研究组均低于对照组,差异均有统计学意义(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。治疗前,两组躯体、心理、社会人际关系评分比较,差异均无统计学意义(P>0.05);治疗后,两组躯体、心理、社会人际关系评分均高于治疗前,且研究组均高于对照组,差异均有统计学意义(P<0.05)。结论:乳腺增生症患者采用西黄胶囊联合他莫昔芬治疗,可进一步下调患者血清中VEGF、bFGF表达水平,降低性激素水平,改善疾病临床症状,改善生活质量,且不会增加药物不良反应,安全性较高,值得临床推广。Objective:To investigate the clinical effect of Xihuang Capsules combined with Tamoxifen in the treatment of breast hyperplasia and its influence on sex hormone indexes.Method:A total of 106 patients with breast hyperplasia treated in Jiamusi Maternal and Child Health Hospital from January 2019 to December 2020 were selected,they were randomly divided into control group and study group,with 53 cases in each group.The control group was treated with Tamoxifen,and the study group was treated with Xihuang Capsules combined with Tamoxifen.The levels of serum vascular endothelial growth factor(VEGF),basic fibroblast growth factor(bFGF),sex hormones [testosterone(T),prolactin(PRL),luteinizing hormone(LH),follicle stimulating hormone(FSH),estradiol(E_(2))],breast symptom score,adverse reactions and quality of life were compared between two groups.Result:After treatment,the levels of serum VEGF and bFGF in both groups were lower than those before treatment,and the study group were lower than those in the control group,the differences were statistically significant(P<0.05).After treatment,the levels of PRL,FSH,LH,and E_(2) in both groups were lower than those before treatment,and the study group were lower than those in the control group,the differences were statistically significant(P<0.05).After treatment,the breast mass hardness,breast mass size and breast pain scores in both groups were lower than those before treatment,and the study group were lower than those in the control group,the differences were statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between two groups(P>0.05).Before treatment,there were no significant differences in physical,psychological and social interpersonal relationship scores between two groups(P>0.05);after treatment,the physical,psychological and social interpersonal relationship scores in both groups were higher than those before treatment,and the study group were higher than those in the control group,the differences were statistica

关 键 词：西黄胶囊 他莫昔芬 乳腺增生症 性激素 

分 类 号：R655.8[医药卫生—外科学]